methyl 2-[(2R,4R)-4-[[(3S)-2-azido-3-methylpentanoyl]amino]-5-methylhexan-2-yl]-1,3-thiazole-4-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[(2R,4R)-4-[[(3S)-2-azido-3-methylpentanoyl]amino]-5-methylhexan-2-yl]-1,3-thiazole-4-carboxylate
• 化学式: C18H29N5O3S
• 分子量: 395.5
• InChiKey: WJNDQQBVLJUVHD-IRYOAWFSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• PROCESSES FOR PREPARING TUBULYSIN DERIVATIVES AND CONJUGATES THEREOF
  申请人：ENDOCYTE, INC.

  公开号：US20140080175A1

  公开（公告）日：2014-03-20

  The invention described herein pertains to processes for preparing tubulysin derivatives, conjugates of tubulysins, and intermediates therefore.
• PROCESSES FOR PREPARING TUBULYSINS
  申请人：ENDOCYTE, INC.

  公开号：US20150225447A1

  公开（公告）日：2015-08-13

  Tubulysins are a series of naturally occurring cytotoxic agents that are of interest as anticancer therapeutic agents. Processes and intermediates useful for preparing naturally occurring and non-naturally occurring tubulysins and analogs and derivatives thereof are described.
• PROCESS FOR PREPARING TUBULYSINS
  申请人：ENDOCYTE, INC.

  公开号：US20160016993A1

  公开（公告）日：2016-01-21

  The invention described herein pertains to processes for preparing tubulysins and derivatives thereof. The invention described herein also pertains to processes for preparing tubulysin conjugates. The invention described herein also pertains to processes for preparing intermediates for preparing tubulysin conjugates. In one step, the alpha-thiazolyl alcohol is protected with triethylsilyl chloride in the presence of imidazole in an aprotic solvent.
• METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES
  申请人：Endocyte, Inc.

  公开号：US20170290878A1

  公开（公告）日：2017-10-12

  The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
• US9273091B2
  申请人：——

  公开号：US9273091B2

  公开（公告）日：2016-03-01